{"id":"NCT00069108","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer","officialTitle":"An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (\"XELOX\") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (\"FOLFOX4\") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-07","primaryCompletion":"2006-08","completion":"2006-08","firstPosted":"2003-09-18","resultsPosted":"2016-02-24","lastUpdate":"2016-04-01"},"enrollment":627,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"5 FU","otherNames":[]},{"type":"DRUG","name":"Leucovorin","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"capecitabine [Xeloda]","otherNames":[]}],"arms":[{"label":"XELOX","type":"EXPERIMENTAL"},{"label":"FOLFOX-4","type":"ACTIVE_COMPARATOR"}],"summary":"This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal cancer. Patients will be randomized to receive either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"Up to 3 years","effectByArm":[{"arm":"XELOX","deltaMin":154,"sd":null},{"arm":"FOLFOX-4","deltaMin":168,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00584"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":87,"countries":["United States","Belgium","Canada","Croatia","Finland","France","Germany","Greece","Israel","Italy","Poland","Puerto Rico","Serbia","Slovakia","Slovenia","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":94,"n":311},"commonTop":["Nausea","Diarrhoea","Fatigue","Vomiting","Neutropenia"]}}